Critical Contrast: Pliant Therapeutics (NASDAQ:PLRX) & Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Valuation and Earnings

This table compares Pliant Therapeutics and Arrowhead Pharmaceuticals”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pliant Therapeutics $1.58 million 27.17 -$149.34 million ($1.45) -0.48
Arrowhead Pharmaceuticals $450.82 million 13.81 -$1.63 million ($5.11) -8.65

Arrowhead Pharmaceuticals has higher revenue and earnings than Pliant Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Pliant Therapeutics and Arrowhead Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pliant Therapeutics 1 1 1 0 2.00
Arrowhead Pharmaceuticals 1 3 10 1 2.73

Pliant Therapeutics currently has a consensus target price of $3.00, indicating a potential upside of 332.78%. Arrowhead Pharmaceuticals has a consensus target price of $98.93, indicating a potential upside of 123.77%. Given Pliant Therapeutics’ higher probable upside, equities research analysts clearly believe Pliant Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Profitability

This table compares Pliant Therapeutics and Arrowhead Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pliant Therapeutics N/A -53.84% -43.00%
Arrowhead Pharmaceuticals -160.64% -133.48% -36.30%

Risk and Volatility

Pliant Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Summary

Pliant Therapeutics beats Arrowhead Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Pliant Therapeutics

(Get Free Report)

Pliant Therapeutics is a biopharmaceutical company focused on developing medicines for fibrotic diseases, in which excess scar tissue can impair the function of organs. The company’s research centers on integrins, proteins involved in processes such as tissue repair and fibrosis. Its investigational programs have included bexotegrast, an oral drug designed to inhibit the αvβ6 and αvβ1 integrins and studied for conditions including idiopathic pulmonary fibrosis. Pliant has also pursued other drug candidates targeting fibrotic disease pathways.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.